title: Intracoronary papaverine but not adenosine reduces regional ventricular function.
abstract: OBJECTIVE
  Whether intracoronary papaverine or adenosine leads to reductions in regional left ventricular function was tested.
  
  
  METHODS
  Fifteen anaesthetised dogs were prepared to record aortic pressure, left ventricular pressure dP/dt, electrocardiogram, regional ventricular shortening, and phasic and mean left circumflex coronary blood flow, and to give intracoronary boluses of papaverine (2, 4, or 6 mg) or adenosine (0.37 and 1.87 mg).
  
  
  RESULTS
  Injected doses were chosen to mimic those given in the clinical setting. Papaverine (6 mg) reduced aortic pressure (mean 96(SD 17) to 89(18) mm Hg; p < 0.05), segmental shortening of the infused left circumflex zone (12(5) to 7(9)%; p < 0.05), and area of the pressure-length loop of the infused zone (120(71) to 53(47) mm.mm Hg; p < 0.05). Papaverine increased coronary blood flow (48(25) to 259(95) ml.min-1; p < 0.05), coronary vascular conductance (0.40(0.20) to 2.93(0.94) ml.mm Hg-1.min-1; p < 0.05), heart rate (88(27) to 100(28) beats.min-1; p < 0.05), and the segmental shortening (17(6) to 19(3)% p < 0.05) and area of the pressure-length loop (130(32) to 177(33) mm.mm Hg; p < 0.05) of the non-infused left anterior descending region. The hyperaemia elicited by papaverine was greater than that of reactive hyperaemia (p = 0.008). Papaverine also increased the QT interval corrected for heart rate (0.35(0.04) to 0.45(0.05) s; p < 0.05). When adenosine was given, coronary blood flow and coronary vascular conductance were increased to similar degrees as those during reactive hyperaemia (41(12) to 210(75) ml.min-1 and 0.46(0.14) to 2.43(0.83) mm Hg.ml-1.min-1, respectively; NS). No effects on segmental shortening or the area of the pressure-length loop in either zone were found. Also, adenosine had no effect on the QT interval.
  
  
  CONCLUSIONS
  These adverse effects of intracoronary papaverine have important implications in its use in patients, particularly in those in whom abnormal cardiac function already exists. Adenosine, on the other hand, seems to be without deleterious effects.
authors.affiliation: Department of Medicine (Cardiology), Carlyle Fraser Heart Center, Emory/Crawford Long Hospital, Atlanta, Georgia 30365.
authors.forename: S E
authors.initials: SE
authors.lastname: Martin
authors.forename: L S
authors.initials: LS
authors.lastname: Schmarkey
authors.forename: D J
authors.initials: DJ
authors.lastname: Oh
authors.forename: R E
authors.initials: RE
authors.lastname: Patterson
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D010208:Papaverine / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects; D016276:Ventricular Function / Q000187:drug effects*
chemical_list: D010208:Papaverine; D000241:Adenosine